Monte Rosa Therapeutics, Inc. (GLUE) Social Stream
MONTE ROSA THERAPEUTICS INC (GLUE) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering GLUE.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-01-25 | 5 | $40 | $20 | $32 | $7.71 | 315.05% |
| 2022-02-08 | 5 | $40 | $15 | $30.75 | $7.71 | 298.83% |
| 2022-04-28 | 6 | $40 | $15 | $28.4 | $7.71 | 268.35% |
| 2022-05-12 | 6 | $38 | $15 | $24.6 | $7.71 | 219.07% |
| 2022-07-27 | 2 | $38 | $15 | $23.25 | $7.71 | 201.56% |
| 2022-08-12 | 5 | $38 | $15 | $23.25 | $7.71 | 201.56% |
| 2022-09-06 | 5 | $37 | $15 | $22.4 | $7.71 | 190.53% |
| 2022-11-11 | 6 | $37 | $15 | $22.333 | $7.71 | 189.66% |
| 2023-03-16 | 6 | $37 | $15 | $22.333 | $7.71 | 189.66% |
| 2023-05-11 | 6 | $36 | $15 | $22.166 | $7.71 | 187.5% |
| 2023-08-14 | 5 | $31 | $15 | $21.2 | $7.71 | 174.97% |
| 2023-10-17 | 5 | $31 | $5 | $19.4 | $7.71 | 151.62% |
| 2023-10-20 | 5 | $22 | $5 | $15.4 | $7.71 | 99.74% |
| 2023-11-09 | 5 | $19 | $5 | $14 | $7.71 | 81.58% |
| 2023-11-10 | 5 | $19 | $5 | $13.8 | $7.71 | 78.99% |
| 2023-12-15 | 6 | $19 | $5 | $13.6 | $7.71 | 76.39% |
The Trend in the Analyst Price Target
Over the past 28 months, GLUE's average price target has gone down $25.73.
Over the past 44 weeks, GLUE's average upside potential has been 261.02%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-03-16 | 6 | 36 | 15 | 22.166 | 7.01 | 216.21% |
| 2023-08-14 | 5 | 31 | 15 | 21.333 | 6.53 | 226.69% |
| 2023-08-14 | 5 | 31 | 15 | 21.200 | 6.53 | 224.66% |
| 2023-10-20 | 5 | 22 | 5 | 15.400 | 2.74 | 462.04% |
| 2023-11-10 | 5 | 19 | 5 | 13.800 | 3.21 | 329.91% |
GLUE Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.33 | 5 | 0 | 1 | 0 | 0 | 6 |
The Trend in the Broker Recommendations
GLUE's average broker recommendation rating improved by 0.34 over the prior 13 months.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- GLUE has a lower variance in analysts' estimates than -1619.09% of all US stocks.
- In terms of how MONTE ROSA THERAPEUTICS INC fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is higher than 1687.35% of that group.
- MONTE ROSA THERAPEUTICS INC's number of analysts covering the stock is greater than 441.23% of all US stocks.
- GLUE has a higher average analyst price target than 515.94% of all US stocks.
In the Pharmaceutical Products industry, ELEV, GRPH, and ABOS are the three stocks most similar to MONTE ROSA THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Is GLUE a Buy, Hold or Sell? See the POWR Ratings now!